Sera Prognostics (NASDAQ:SERA - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a "hold" rating to a "sell" rating in a report released on Friday.
Sera Prognostics Price Performance
NASDAQ:SERA traded down $0.05 during mid-day trading on Friday, reaching $1.55. The stock had a trading volume of 213,677 shares, compared to its average volume of 142,341. Sera Prognostics has a 12 month low of $1.53 and a 12 month high of $9.13. The stock has a market capitalization of $58.39 million, a PE ratio of -1.57 and a beta of 0.71. The stock has a 50-day simple moving average of $2.64 and a two-hundred day simple moving average of $4.79.
Sera Prognostics (NASDAQ:SERA - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.04. The business had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.06 million. Equities analysts expect that Sera Prognostics will post -0.96 EPS for the current year.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of SERA. BNP Paribas Financial Markets acquired a new position in Sera Prognostics in the 4th quarter worth about $28,000. XTX Topco Ltd acquired a new stake in shares of Sera Prognostics during the first quarter valued at about $39,000. Price T Rowe Associates Inc. MD bought a new stake in shares of Sera Prognostics during the fourth quarter worth about $93,000. Gotham Asset Management LLC acquired a new position in shares of Sera Prognostics in the fourth quarter valued at approximately $96,000. Finally, Walleye Capital LLC acquired a new position in shares of Sera Prognostics in the fourth quarter valued at approximately $98,000. 54.64% of the stock is currently owned by institutional investors and hedge funds.
About Sera Prognostics
(
Get Free Report)
Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Sera Prognostics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sera Prognostics wasn't on the list.
While Sera Prognostics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
